icad (ICAD) ROCE % : -6.04% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is icad ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. icad's annualized ROCE % for the quarter that ended in Dec. 2023 was -6.04%.

icad ROCE % Historical Data

The historical data trend for icad's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

icad ROCE % Chart

icad Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-61.46

-55.38

-25.80

-23.45

-19.13

icad Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-24.77	-41.41	-20.67	-12.27	-6.04

icad ROCE % Calculation

icad's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-6.974	/	( ( (51.705 - 13.452)	+	(41.418 - 6.748) )	/ 2 )
	=	-6.974	/	( (38.253	+	34.67)	/ 2 )
	=	-6.974	/	36.4615
	=	-19.13 %

icad's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-2.088	/	( ( (45.828 - 11.412)	+	(41.418 - 6.748) )	/ 2 )
	=	-2.088	/	( ( 34.416	+	34.67 )	/ 2 )
	=	-2.088	/	34.543
	=	-6.04 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

icad (NAS:ICAD) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

icad ROCE % Related Terms

Thank you for viewing the detailed overview of icad's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

icad (ICAD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » icad Inc (NAS:ICAD) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

98 Spit Brook Road, Suite 100, Nashua, NH, USA, 03062

Website

https://www.icadmed.com

icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company reports in two segments: Detection and Therapy. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. In the Therapy segment, the Company offers the Xoft System, an isotope-free cancer treatment platform technology. The Xoft System can be used for the treatment of early-stage breast cancer, endometrial cancer, cervical cancer and nonmelanoma skin cancer.

Executives

Eric Lonnqvist	officer: See Remarks	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 02062
Daniel Joseph Shea	officer: See Remarks	2 MINUTEMAN ROAD, MEDFIELD MA 02052
Jonathan Go	officer: Sr. VP of R&D	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Stephen P Sarno	officer: See Remarks	C/O SAPIENT CORPORATION, 25 FIRST STREET, CAMBRIDGE MA 02141
Andy Sassine	director	82 DEVONSHIRE STREET, BOSTON MA 02109
Dana R Brown	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Timothy Norris Irish	director	98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Nathaniel Dalton	director	C/O AFFILIATED MANAGERS GROUP INC, 777 S. FLAGLER DR., SUITE 1201 E. TOWER, WEST PALM BEACH FL 33401
Susan Alyson Wood	director	845 MORENO AVENUE, PALO ALTO CA 94303
Michael S Klein	director	C/O ICAD INC, 98 SPIT BROOK ROAD SUITE 100, NASHUA NH 03062
Charles Ross Carter	officer: See Remarks	C/O GI DYNAMICS, INC., 745 ATLANTIC AVENUE, BOSTON MA 02111
Stacey M Stevens	officer: Executive VP of Marketing	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
R. Scott Areglado	officer: Interim Chief FinancialOfficer	98 SPIT BROOK ROAD, SUITE 100, C/O ICAD, INC., NASHUA NH 03062
Rakesh Patel	director	15400 NATIONAL AVENUE, LOS GATOS CA 95032
Dr Lawrence Howard	director	C/O PRESSTEK INC, 2 GREENWICH OFFICE PARK, GREENWICH CT 06831